Published January 29, 2024 | Version v1
Journal article Open

ASSESSMENT OF THE STATE OF POST-VACCINATION IMMUNITY TO MEASLES IN CHILDREN WITH POST-CAVID LONG SYNDROME AND OPTIMIZATION OF PREVENTIVE MEASURES TO REDUCE THE INCIDENCE OF MEASLES

Creators

  • 1. Termez branch of Tashkent medical academy

Description

Patients with juvenile idiopathic arthritis (JIA) may have low protective levels of antibodies to vaccine antigens due to the immunologic features of the disease, disrupted vaccination schedules, and use of immunosuppressive medications. The purpose of the study was to study the state of post-vaccination immunity and determine the factors associated with the preservation of the protective level of antibodies in patients with JIA.

Files

232-239 Kenjayeva Dilorom Toshtemirovna.pdf

Files (933.6 kB)

Name Size Download all
md5:6a986384831afb26830e4bf1d002fc5d
933.6 kB Preview Download

Additional details

References

  • 1. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007; 369(9563):767–778. doi: 10.1016/S0140-6736(07)60363-8.
  • 2. Cassidy JT, Petty RE. Textbook of pediatric rheumatology. Elsevier Saunders; 2005. 792 р.
  • 3. Beukelman T, Xie F, Chen L, et al; SABER Collaboration. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthrit Rheum. 2012;64(8):2773–2780. doi: 10.1002/art.34458.
  • 4. Salvana EM, Salata RA. Infectious complications associated with monoclonal antibodies and related small molecules. Clin Microbiol Rev. 2009;22(2):274–290. doi: 10.1128/CMR.00040-08.
  • 5. Giancane G, Swart J, Bovis F, et al. Risk of infections in juvenile idiopathic arthritis patients treated with biologic agentsand/or methotrexate: results from pharmachild registry. Abstract number: 3116. Available from: https://acrabstracts.org/abstract/risk-ofinfections-in-juvenile-idiopathic-arthritis-patients-treated-withbiologic-agentsandor-methotrexate-results-from-pharmachildregistry/.
  • 6. Abinun M, Lane JP, Wood M, et al. Infection-related death among persons with refractory juvenile idiopathic arthritis. Emerg Infect Dis. 2016;22(10):1720–1727. doi: 10.3201/eid2210.151245.
  • 7. Castillo RD, De la Pena W, Marzan KA. Diagnosis and management of infectious complications of childhood rheumatic diseases. Curr Rheumatol Rep. 2013;15(4):322. doi: 10.1007/ s11926-013-0322-6.
  • 8. Heijstek MW, Ott de Bruin LM, Bijl M, et al.; EULAR. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis. 2011;70(10):1704–1712. doi: 10.1136/ ard.2011.150193.
  • 9. Heijstek MW, van Gageldonk PG, Berbers GA, et al. Differences in persistence of measles, mumps, rubella, diphtheria and tetanus antibodies between children with rheumatic disease and healthy controls: a retrospective cross-sectional study. Ann Rheum Dis. 2012;71(6):948–954. doi: 10.1136/annrheumdis-2011-200637.
  • 10. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–392.